Abstract:Liver cancer patients had stable and moderate levels of QOL during SRT. Factors related to QOL across the 6 weeks were multi-dimensional. Both overall symptom severity and selected individual symptoms were important to patients' QOL. These factors should all be carefully assessed and clinically treated to enhance liver cancer patients' QOL during SRT.
“…This study also found that there appears to be differences in the reporting of PWB, EWB, and overall QOL between cancer diagnosis groups. Those diagnosed with breast cancer reported higher PWB and overall QOL scores but lower EWB score compared with those with liver cancer, for liver cancer patients often suffer multiple symptoms that may have a negative effect on overall QOL, especially physical well-being [36,37], while breast cancer patients usually feel angry, anxious or distressful, and other negative moods due to loss of body image [38]. Additionally, treatment-related variables such as previous treatments and the number of kinds of previous treatments appeared to be meaningful factors for explaining the variance in PWB and FWB.…”
The patients had relatively poorer QOL as compared with the US and Australian general populations. The factors related to QOL need to be considered in the palliative care of Chinese advanced cancer patients at home. QOL improvement can be achieved to some extent by effective symptom management, especially by alleviating emotional distress. The cut-point for QOL was statistically significant, and further studies are needed to define a clinically meaningful cut-point.
“…This study also found that there appears to be differences in the reporting of PWB, EWB, and overall QOL between cancer diagnosis groups. Those diagnosed with breast cancer reported higher PWB and overall QOL scores but lower EWB score compared with those with liver cancer, for liver cancer patients often suffer multiple symptoms that may have a negative effect on overall QOL, especially physical well-being [36,37], while breast cancer patients usually feel angry, anxious or distressful, and other negative moods due to loss of body image [38]. Additionally, treatment-related variables such as previous treatments and the number of kinds of previous treatments appeared to be meaningful factors for explaining the variance in PWB and FWB.…”
The patients had relatively poorer QOL as compared with the US and Australian general populations. The factors related to QOL need to be considered in the palliative care of Chinese advanced cancer patients at home. QOL improvement can be achieved to some extent by effective symptom management, especially by alleviating emotional distress. The cut-point for QOL was statistically significant, and further studies are needed to define a clinically meaningful cut-point.
“…This constitutes preliminary evidence of the existence of co-occurring symptoms in patients with sleep disturbance, which is consistent with the literature on hepatocellular carcinoma patients undergoing TACE treatment. 6,7,17 The evidence related to sleep disturbance in hepatocellular carcinoma patients undergoing TACE treatment calls for advanced research in this area. Our research revealed patients' experience with sleep disturbance, as well as determinants, consequences, and potential interventions.…”
Section: The Determinants Of Presence or Absence Of Sleep Disturbancementioning
confidence: 99%
“…6,7,17,31 Fatigue was identified as one of the most common problems and most important predictors of sleep disturbance. Although the findings of different studies are consistent, the cause-and-effect relationships between fatigue and sleep disturbance are unclear.…”
Section: The Determinants Of Presence or Absence Of Sleep Disturbancementioning
confidence: 99%
“…15 Hugel et al 16 reported that uncontrolled symptoms were the most common cause of sleep disturbance, reported by 60% of patients. Previous studies have revealed an association between sleep problems and physical functioning, 5 pain, 5 emotional reactions, 5,6 and fatigue 6,7,17 in patients with hepatocellular carcinoma. Hepatocellular carcinoma patients undergoing treatment often experience multiple symptoms, including fatigue, 6,11,17 pain, 11 weight loss, 11 and poor appetite.…”
“…1 summarizes the review process. Of 2181 initially screened studies, 4 met all inclusion criteria (Klein et al, Shun et al, Mendez Romero et al, Thibault et al) and were analysed, with one additional study having met criteria after being identified from a grey literature search (Law et al) [18–22]. Fig.…”
BackgroundStereotactic ablative radiotherapy (SABR) is a safe and effective modality in patients with liver cancer who are ineligible for other local therapies. However SABR is not current standard of practice and requires further validation. Patient reported quality of life (QOL) is key to this validation, yet no systematic reviews to date have been performed to analyse QOL following liver SABR. QOL is a critical part of therapy evaluation, particularly in disease states with short life expectancy. The purpose of this study was to conduct a systematic review of QOL outcomes for liver SABR.Materials and methodsMEDLINE and EMBASE databases from 1996 to October 2015 were queried to obtain English language studies analysing QOL following liver SABR. Included studies described patient-reported QOL as either a primary or secondary endpoint, and analysed QOL change over time. Studies were screened, and relevant data were abstracted and analysed.ResultsOf 2181 initially screened studies, 5 met all inclusion criteria. Extracted studies included a total of 392 eligible patients with hepatocellular carcinoma, liver metastases and intrahepatic cholangiocarcinoma. Four studies were prospective in design, and only one study was a conference abstract. Extracted studies were heterogeneous in dose prescription used (11–70 Gy in 3–30 fractions), in addition to reported QOL metrics (EORTC QLQ C-15 PAL,/C-30/LM-21, EuroQol 5D, FACT-Hep, FLIC) and final endpoints (range 6 weeks to 12 months). Despite this there were few statistically significant declines in QOL scores following SABR. Four studies demonstrated transient fatigue in the first 1–4 weeks, while 2 studies showed transient worsening of appetite at 1 month. In all but one instance (loss of appetite at 6 weeks), levels returned to insignificant difference baseline by the final endpoints. All studies showed no significant QOL decline in any domain at their respective endpoints. In studies with overlapping QOL tools, estimates of 3-month post SABR global QOL were similar.ConclusionResults of this systematic review demonstrate well-preserved post liver SABR QOL. These findings strengthen the argument for liver SABR, and should aim to support future comparative effectiveness trials with other local modalities including surgery, chemoembolization and radiofrequency ablation, with a focus on QOL outcomes as an important endpoint.Electronic supplementary materialThe online version of this article (doi:10.1186/s13014-017-0818-8) contains supplementary material, which is available to authorized users.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
